Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) vs Eli Lilly And Co (LLY) Price & Performance

ProShares UltraShort Bloomberg Natural Gas ETFTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

ProShares UltraShort Bloomberg Natural Gas ETF vs Eli Lilly And Co — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $28.22, while Eli Lilly And Co trades at $1,208.76 (market cap $1.08T). The key difference: Eli Lilly And Co pays a 0.57% dividend while ProShares UltraShort Bloomberg Natural Gas ETF pays none. Which is the better fit depends on your goals.

KOLDLLY
Sector
Leveraged / InverseHealth
52-Week High
$49.39$1.24K
52-Week Low
$13.58$639.43
Market Cap
$1.08T
Enterprise Value
$1.13T
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ProShares UltraShort Bloomberg Natural Gas ETF

KOLD trades at $28.035, down 2.11% today, with technical indicators showing a bullish bias despite recent weakness. The stock faces strong resistance at $29-$30 levels while finding support at $28. Natural gas market volatility continues to drive price action, with weather forecasts and LNG export flows being key near-term catalysts. Recent news highlights steady natural gas futures trading amid mixed demand signals.

The outlook remains tactical given KOLD's leveraged exposure to natural gas price movements. Upside potential exists if weather-driven demand strengthens, but risks include production increases and storage levels. Investors should monitor EIA storage reports and global LNG demand trends for directional cues in this volatile energy sector ETF.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ProShares UltraShort Bloomberg Natural Gas ETF

KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.

Read more on KOLD

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY